• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int Immunopharmacol . Increased inflammatory mediators levels are associated with clinical outcomes and prolonged illness in severe COVID-19 patien

tetano

Editor, Senior Moderator
Int Immunopharmacol


. 2023 Aug 8;123:110762.
doi: 10.1016/j.intimp.2023.110762. Online ahead of print. Increased inflammatory mediators levels are associated with clinical outcomes and prolonged illness in severe COVID-19 patients

Wendong Hao[SUP] 1 [/SUP], Meimei Liu[SUP] 2 [/SUP], Cairong Bai[SUP] 3 [/SUP], Xin Liu[SUP] 2 [/SUP], Siqian Niu[SUP] 4 [/SUP], Xiushan Chen[SUP] 4 [/SUP]



Affiliations
Abstract

Objective: The purpose of this study was to identify potential predictors of clinical outcome in severe COVID-19 patients and to investigate the relationship between immunological parameters and duration of illness.
Methods: This single-center study retrospectively recruited 73 patients with severe or critical COVID-19. Immunological indicators include white blood cell count, neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio, and circulating inflammatory mediators were observed for their association with disease severity, mortality and duration of illness of COVID-19.
Results: Serum inflammatory mediators levels of C-reactive protein (P = 0.015), interleukin 6 (IL-6) (P < 0.001), CX3CL1 (P < 0.001), D-dimer (P < 0.001) and procalcitonin (PCT) (P < 0.001) were increased in critical illness patients compared to those severe COVID-19 patients. CX3CL1 has the highest C-index (0.75) to predict in-hospital mortality in patients with COVID-19. Furthermore, this study shows for the first time that the duration of illness in severe COVID-19 patients is associated with serum levels of CX3CL1 (P = 0.037) and D-dimer (P = 0.014).
Conclusion: CX3CL1, D-dimer, PCT, and IL-6 could effectively predict mortality in severe COVID-19 patients. In addition, only the circulating levels of CX3CL1 and D-dimer were significantly associated with duration of illness.

Keywords: CX3CL1; Coronavirus disease 2019; D-dimer; Interleukin 6; Severe acute respiratory syndrome coronavirus-2.

 
Back
Top Bottom